Hemin
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Heme Arginate; Belgium: Normosang; Denmark: Normosang; Estonia: Normosang; Finland: Normosang; France: Normosang; Germany: Heme Arginate, Normosang; Greece: Normosang; Hungary: Normosang; Ireland: Normosang; Italy: Normosang; Latvia: Normosang; Lithuania: Normosang; Malta: Normosang; Netherlands: Humaan hemine, Normosang; Poland: Human Hemin, Normosang; Portugal: Normosang; Slovakia: Normosang; Slovenia: Normosang; Spain: Normosang; Sweden: Normosang; UK: Normosang.
Drug combinations
Chemistry
Pharmacologic Category
Other Hematological Agents. Blood Modifiers. (ATC-Code: BO6AB).
Mechanism of action
Inhibits hepatic and/or marrow synthesis of ALA synthase, the enzyme which regulates porphyrin/heme pathway.
Therapeutic use
Treatment of recurrent attacks of acute intermittent porphyria.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to hemin or any component of the formulation. Porphyria cutanea tarda.
Warnings and precautions
Intended to prevent porphyria attacks from becoming critical (not intended to repair neuronal damage resulting from attacks). Product of human plasma (may potentially contain infectious agents which could transmit disease).